logo-loader
RNS
ValiRx PLC

ValiRx PLC - Conclusion of Evaluation with University of Dundee

RNS Number : 1731J
ValiRx PLC
22 June 2026
 

22 June 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

Conclusion of Evaluation with University of Dundee

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update at the conclusion of the Evaluation Agreement with the University of Dundee and their Drug Discovery Unit (DDU) announced on 12 February 2024 and extended as announced on 30 January 2025.

Under the terms of the Extended Evaluation Agreement, ValiRx supported continued mechanism of action studies, provided by the research group of Professor Cleo Bishop (Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility), funded by a £50,000 grant from the Queen Mary University London Impact Fund. ValiRx contributed £9,000 and in-silico modelling with in-kind support from Inaphaea Biolabs Ltd.

 

Despite progress on the target deconvolution at the conclusion of the evaluation period, the technology had not met the strict criteria for the Company to exercise its option to license the technology on pre-agreed terms. The parties have agreed to terminate the current collaboration agreement and revert responsibility for maintaining the intellectual property to DDU and Queen Mary University.

 

Mark Eccleston, CEO of ValiRx commented "As noted when we announced the extension of the evaluation, a key decision point for in-licensing the asset was determination of the precise mechanism of action and, while progress has been made in Professor Bishop's laboratory, funded largely through non-dilutive funding, this criterion was not met. We're pleased that work carried out under the grant we supported has undoubtedly added value to the programme but, as we've discussed, the strict and robust criteria for asset selection and progression are designed to ensure we only progress assets we believe we can generate shareholder value from within a readably rapid timescale.

 

The Directors of the Company take responsibility for this announcement.

 

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

Investor questions on this announcement

We encourage all investors to share questions

on this announcement via our investor hub

 

https://valirx.com/link/yEv6pe

 

ValiRx plc

Dr Mark Eccleston, CEO

Tel: +44 115 784 0026

www.valirx.com

Mark.Eccleston@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Shard Capital Partners LLP (Sole Broker)

Damon Heath

Tel: +44 (0) 20 7186 9000

V Formation (Public Relations)

Jocelyn Braithwaite

+44 (0) 115 646 5491

 www.vformation.co.uk/jocelyn@vformation.co.uk

 

Subscribe to our news alert service: https://valirx.com/s/f298d1

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFBMFTMTMTBLF
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read